Laquinimod (DB06685): A Comprehensive Analysis of a Novel Aryl Hydrocarbon Receptor Activator from Multiple Sclerosis to Ophthalmology

Section 1: Compound Profile and Chemical Synthesis

1.1. Identifiers and Structural Characteristics

Laquinimod is an investigational small molecule immunomodulator classified chemically as a quinoline-3-carboxamide derivative.[1] It has been assigned the DrugBank accession number DB06685 and the Chemical Abstracts Service (CAS) Registry Number 248281-84-7.[1] For regulatory and tracking purposes, it is also identified by the Unique Ingredient Identifier (UNII) 908SY76S4G.[3]

The compound's formal chemical name, according to the International Union of Pure and Applied Chemistry (IUPAC), is 5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide.[3] Throughout its development and in scientific literature, Laquinimod has been referred to by numerous synonyms and codes. These include the primary development code ABR-215062 (and its variants ABR 215062), the code TV-5600, and the proposed brand name Nerventra.[1]

The molecular structure of Laquinimod is defined by the chemical formula C19​H17​ClN2​O3​.[3] Its structure is captured by standard chemical notation systems, including the Simplified Molecular Input Line Entry System (SMILES) string

CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O and the International Chemical Identifier (InChI) key GKWPCEFFIHSJOE-UHFFFAOYSA-N.[3] These identifiers provide an unambiguous representation of its atomic composition and connectivity.

1.2. Physicochemical and Computed Properties

Laquinimod is a synthetic organic compound that presents as a solid, off-white to beige powder under standard conditions.[6] Its molecular weight (molar mass) is consistently reported as approximately 356.8 g/mol.[1]